Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 1275 (ustekinumab) in Active Psoriatic Arthritis
NCT00267956Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing CNTO1275 (ustekinumab) with Placebo (2 arms). Primary endpoint: American College of Rheumatology 20 Response at 12 weeks. Started Dec 2005; status: completed.
02
Drugs
ustekinumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00267956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267956.